Poster Session B
Sunday, Dec. 2, 2018
12–2:15 p.m.

B01 Simultaneous targeting of mTOR and mLST8 in human breast cancer cells. Melissa Coyle, Chapman University, Irvine, CA, USA.

B02 Combined inhibition of mTOR and Src family kinases enhances treatment effects in prostate cancer cells. Yao Dai, University of Florida, Gainesville, FL, USA.

B03, PR03 Selective degradation of mutant PIK3CA promotes increased mutant specificity in a subset of PI3K ATP-competitive inhibitors. Nicholas Endres, Genentech, South San Francisco, CA, USA.


B05 mEAK-7 supports self-renewal and radioresistance in metastatic cancer. Fatima Haidar, The University of Michigan, Ann Arbor, MI, USA.

B06 Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses Kras-mutated non-small cell lung cancer. Ling-hua Meng, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

B07 TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Nicci Owusu-Brackett, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B08 Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (nab-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition. Anita Schmid, Aadi Bioscience, Pacific Palisades, CA, USA.

B09 Structural biology of the PI3K pathway: On with phosphorylation, down with ubiquitination. Sandra Gabelli, The Johns Hopkins University, Baltimore, MD, USA.

B10, PR02 Structural and functional analyses of GATOR1, a negative regulator of the mTORC1 pathway. Kuang Shen, Whitehead Institute for Biomedical Research, Cambridge, MA, USA.

B11 mTOR pathway inhibition induces GPNMB expression and sensitizes breast cancer cells to an antibody drug conjugate targeting GPNMB. Marco Biondini, McGill University, Montréal, QC, Canada.

B12 Examining EGFR-mediated PI3K/Akt pathway in combination therapy of cetuximab and dynamin inhibition. Hui Yi Chew, The University of Queensland Diamantina Institute, Brisbane, QLD, Australia.
Poster Session B
Sunday, Dec. 2, 2018
12–2:15 p.m.

B13 Targeting mTOR/JUN/AXL pathway in TSC-related tumors. Heng Du, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

B14 Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC. Kathy Gately, Trinity College Dublin/St James’s Hospital, Dublin, Ireland.

B15 Investigating the contribution of mTORC1-dependent stromal signaling to cancer onset in Li-Fraumeni Syndrome. Camilla Giovino, The Hospital for Sick Children, Toronto, ON, Canada.

B16, PR10 PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. Ecaterina Ileana Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B17 Activating mutations of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene confer sensitivity to PD-L1 checkpoint inhibition in metastatic adenocarcinoma patients. Maliha Nusrat, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B18 Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer. Maria Rubinstein, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

B19 Susceptibility of NOTCH1 mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition via PDK1. Vaishnavi Sambandam, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B20, PR08 AKT mutant allele-specific activation dictates pharmacologic sensitivities. Tripti Shrestha Bhattarai, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

B21 Protein quantitation assays for Akt, PI3K p110α, and PTEN to assess PI3K pathway activity in tumor tissue. Constance Sobsey, McGill University, Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.

B22 Investigation of PTEN genotype-phenotype correlations in the PTEN Hamartoma Tumour Syndrome (PHTS) using in vitro and in vivo approaches. Priyanka Tibarewal, Cancer Institute, University College London, London, United Kingdom.

B23 Genomic sequencing of metastatic hormone-receptor positive breast cancer implicates AKT1 in driving resistance to cyclin-dependent kinase 4/6 inhibitors. Seth Wander, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
B24 Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Yan Xing, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B25 Development of a nanoparticle containing the PI3K/mTOR dual Inhibitor, gedatolisib, for cancer therapy. Lianglin Zhang, Pfizer Inc, San Diego, CA, USA.

B26 Role of AKT3 in EGFR-TKI resistance of non-small cell lung cancer. Ching-Chow Chen, Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.

B27 MTORC1/2 inhibition as a treatment strategy for PIK3CA mutant colorectal cancer. Rebecca DeStefanis, UW-Madison, Madison, WI, USA.

B28 Estrogen receptor alpha (ERa) promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f). Marina Holz, New York Medical College, Valhalla, NY, USA.

B29 Targeting EZH2 and PI3K/mTOR for a novel combination therapeutic strategy in aggressive variant prostate cancer. Katherine Morel, Dana-Farber Cancer Institute, Boston, MA, USA.

B30, PR06 Developmentally regulated mTOR degradation in normal and malignant hematopoiesis. Christina Spevak, NYU Health, New York, NY, USA.

B31 Single-cell multiplex immunofluorescence of formalin-fixed paraffin-embedded prostate cancer tissue identifies PI3K pathway activation in two prospective cohort studies. Konrad Stopsack, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

B32 A specialized post-transcriptional program in chemoresistant, quiescent cancer cells. Shobha Vasudevan, Mass General Hospital-Harvard Medical School, Boston, MA, USA.

B33 Targeting PI3K/mTOR signaling with potent, selective and orally-available small molecule inhibitors of eIF4E. Kevin Webster, eFFECTOR Therapeutics, San Diego, CA, USA.

B34 PI3K/p110β modulates tumor suppressor gene NR0B2 expression in human liver cancer cells. Jean Li, KUMC, Kansas City, KS, USA.